We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Tops Q3 Earnings, FY16 View Up
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, reported third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents and surged 19.5% on currency-neutral basis.
Quarter Details
At comparable currency-neutral basis, revenues climbed 3.9% to $3.20 billion, which was marginally better than the Zacks Consensus Estimate of $3.19 billion.
BD medical revenues grew 3% year over year to almost $2.24 billion. Medication and Procedural solution sales grew 2.1%, while Diabetes care, Medication Management solutions and Pharmaceutical revenues increased 6.6%, 6.2% and 1.5%, respectively.
BD Lifesciences revenues increased 6% from the year-ago quarter to $963 million. Preanalytical Systems, Diagnostics Systems and BD Biosciences revenues improved 6.6%, 9.5% and 1.2% on a year-over-year basis, respectively.
The upside in the Diagnostic Systems was driven by strong core microbiology sales including BD Kiestra during the quarter. Within the Biosciences unit, strong growth in research instruments and reagents in the U.S. was partially neutralized by declines in Africa, in line with management expectations.
Geographically, U.S. revenues increased 3.4% to roughly $1.74 billion, while International revenues were up 4.6% on a currency-neutral basis to $1.46 billion.
For fiscal 2016, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 24.5% to 25%. BD continues to estimate organic revenue growth of approximately 4.5% to 5%.
Meanwhile, adjusted earnings (on a currency-neutral basis) are now expected in the range of $9.08 to $9.15 up from previous guidance of $9.01 to $9.08, reflecting year-over-year growth of 27% to 28%.
Zacks Rank & Key Picks
Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include Halyard Health , Merit Medical (MMSI - Free Report) and Align Technology (ALGN - Free Report) . While Halyard Health and Merit Medical sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton, Dickinson (BDX) Tops Q3 Earnings, FY16 View Up
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, reported third-quarter fiscal 2016 earnings of $2.35 per share, which beat the Zacks Consensus Estimate by 16 cents and surged 19.5% on currency-neutral basis.
Quarter Details
At comparable currency-neutral basis, revenues climbed 3.9% to $3.20 billion, which was marginally better than the Zacks Consensus Estimate of $3.19 billion.
BD medical revenues grew 3% year over year to almost $2.24 billion. Medication and Procedural solution sales grew 2.1%, while Diabetes care, Medication Management solutions and Pharmaceutical revenues increased 6.6%, 6.2% and 1.5%, respectively.
BD Lifesciences revenues increased 6% from the year-ago quarter to $963 million. Preanalytical Systems, Diagnostics Systems and BD Biosciences revenues improved 6.6%, 9.5% and 1.2% on a year-over-year basis, respectively.
The upside in the Diagnostic Systems was driven by strong core microbiology sales including BD Kiestra during the quarter. Within the Biosciences unit, strong growth in research instruments and reagents in the U.S. was partially neutralized by declines in Africa, in line with management expectations.
Geographically, U.S. revenues increased 3.4% to roughly $1.74 billion, while International revenues were up 4.6% on a currency-neutral basis to $1.46 billion.
BECTON DICKINSO Price, Consensus and EPS Surprise
BECTON DICKINSO Price, Consensus and EPS Surprise | BECTON DICKINSO Quote
Guidance
For fiscal 2016, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 24.5% to 25%. BD continues to estimate organic revenue growth of approximately 4.5% to 5%.
Meanwhile, adjusted earnings (on a currency-neutral basis) are now expected in the range of $9.08 to $9.15 up from previous guidance of $9.01 to $9.08, reflecting year-over-year growth of 27% to 28%.
Zacks Rank & Key Picks
Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include Halyard Health , Merit Medical (MMSI - Free Report) and Align Technology (ALGN - Free Report) . While Halyard Health and Merit Medical sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>